What is the impact factor of biomaterials?
12.48Biomaterials / Impact Factor (2020)
Is biomaterials science a good journal?
It is published by Royal Society of Chemistry. The overall rank of Biomaterials Science is 2479. According to SCImago Journal Rank (SJR), this journal is ranked 1.422. SCImago Journal Rank is an indicator, which measures the scientific influence of journals.
Is biomaterials open access?
Articles are freely available to both subscribers and the wider public with permitted reuse. Articles are made available to subscribers as well as developing countries and patient groups through our access programs. An open access publication fee is payable by authors or their research funder.
Why biomaterials is an important part of bioengineering?
Biomaterials play an integral role in medicine today—restoring function and facilitating healing for people after injury or disease. Biomaterials may be natural or synthetic and are used in medical applications to support, enhance, or replace damaged tissue or a biological function.
Why do we need biomaterials?
What are APC’s piezoelectric materials?
APC’s piezoelectric materials are known in the industry for their purity and low variability in mechanical and electrical properties. APC’s piezo materials fall into two broad categories: hard piezo material and soft piezo material.
What is biomaterials?
Biomaterials is an international journal covering the science and clinical application of biomaterials. A biomaterial is now defined as a substance that has been engineered to take a form which, alone or as part of a complex system, is used to direct, by control of interact… Read more.
What materials are used to make aAPCs?
The materials which have been used for aAPCs have ranged from biomimetic or biological such as liposomes or cell membranes, to inorganic such as iron oxide or carbon nanotubes, to polymeric such as polystyrene or poly (lactic-co-glycolic acid) (PLGA), or some combination thereof ( Fig. 2 C).
Why Biomaterial platforms for T cell expansion?
Furthermore, biomaterial platforms for T cell expansion can allow for control of the dosing, timing, and localization of ETC, CAR, or TCR therapies in vivo to maintain antitumor immune responses and maximize their efficacy, while minimizing the risks of off-target toxicities, T cell exhaustion, or immune escape.